Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Rafael Holdings, Inc. (RFL) Create: Alert

All | News | Filings
Date FiledTypeDescription
12/03/2019 GN Data on Rafael Pharmaceuticals' CPI-613® (devimistat) in Patients with Relapsed Burkitt Lymphoma to be Presented at the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition
12/03/2019 GN Timothy Pardee, M.D., Ph.D., Co-Chief Medical Officer of Rafael Pharmaceuticals, to Present on CPI-613® (devimistat) in Relapsed/Refractory Acute Myeloid Leukemia (AML) at the 2019 American Society of Hematology (ASH) Annual Meeting & Expos
12/02/2019 25 Form 25 - Notification of the removal from listing and registration of matured, redeemed or retired securities:
12/02/2019 GN Rafael Pharmaceuticals Announces Expansion of Phase 2 Trial of CPI-613® (devimistat) for Patients with Relapsed or Refractory Burkitt's Lymphoma/Leukemia to Massachusetts General Hospital in Boston
11/21/2019 DEF 14A Form DEF 14A - Other definitive proxy statements:
11/18/2019 CERT Form CERT -
11/18/2019 8-A12B Form 8-A12B - Registration of securities [Section 12(b)]:
11/18/2019 8-K Quarterly results
10/30/2019 GN Rafael Pharmaceuticals Appoints Chief Medical Officer, José Octávio Costa Filho, M.D.
10/24/2019 GN Rafael Pharmaceuticals Announces Expansion into South Korea of Pivotal Phase 3 Trial of CPI-613® (devimistat) in Patients with Metastatic Pancreatic Cancer
10/04/2019 10-K Annual Report for the period ended July 31, 2019
10/03/2019 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Rafael Holdings Reports Fourth Quarter and Full Fiscal Year 2019 Results"
10/02/2019 GN Rafael Pharmaceuticals Appoints Wendy McDermott to Chief People Officer
09/26/2019 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
Docs: "Rafael Holdings, Inc. Second Amended and Restated By-Laws (as amended on September 23, 2019)"
09/24/2019 4 Polinsky David (CFO) has filed a Form 4 on Rafael Holdings, Inc.
Txns: Granted 5,000 shares @ $0
09/19/2019 GN Rafael Pharmaceuticals Announces Expansion into South Korea of Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (devimistat) in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
09/16/2019 GN Peer-Reviewed Journal Future Oncology Publishes Two Manuscripts on Cancer Metabolism and Drug Candidate CPI-613® (Devimistat)
08/08/2019 8-K Unregistered Sales of Equity Securities
08/08/2019 4 JONAS HOWARD S (CEO) has filed a Form 4 on Rafael Holdings, Inc.
Txns: Acquired 1,849,749 shares @ $8.47, valued at $15.7M
07/30/2019 GN David A. Polinsky, Esq Appointed to the Board of Directors of Innovative Food Holdings, Inc.
07/25/2019 4 JONAS HOWARD S (CEO) has filed a Form 4 on Rafael Holdings, Inc.
Txns: Disposed of 1,265,804 shares @ $0
Acquired 1,265,804 shares @ $0
07/22/2019 8-K/A Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits
Docs: "Letter from Zwick & Banyai, PLLC to the Securities and Exchange Commission"
07/18/2019 8-K Changes in Registrant's Certifying Accountant
07/18/2019 GN Rafael Pharmaceuticals Announces Expansion into Israel of Pivotal Phase 3 Trial (AVENGER 500) of CPI-613®? (devimistat) in Combination with Modified FOLFIRINOX as First-Line Treatment for Patients with Metastatic Pancreatic Cancer
06/06/2019 GN Sanjeev Luther, President and CEO of Rafael Pharmaceuticals, Named Finalist for The 2019 EY Entrepreneur Of The Year® Award in New Jersey
06/05/2019 10-Q Quarterly Report for the period ended April 30, 2019
06/05/2019 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Rafael Holdings Reports Third Quarter Fiscal Year 2019 Results"
05/16/2019 GN Sanjeev Luther, President and CEO of Rafael Pharmaceuticals, to be Honored by American Cancer Society at Annual Starry Night Gala
03/29/2019 GN LipoMedix to Present New Clinical Data on Promitil® at American Association for Cancer Research (AACR) Annual Meeting 2019
03/12/2019 10-Q Quarterly Report for the period ended January 31, 2019
03/12/2019 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Rafael Holdings Reports Second Quarter Fiscal Year 2019 Results"
03/04/2019 GN Lipomedix Announces Initiation of Phase 1b Trial (LIPORAD-2018) of Promitil® in Combination with Radiotherapy in Patients with Advanced Cancer.
02/08/2019 SC 13G DIMENSIONAL FUND ADVISORS LP reports a 7.1% stake in RAFAEL HOLDINGS INC-CLASS B
01/28/2019 4 ASH MENACHEM (President) has filed a Form 4 on Rafael Holdings, Inc.
Txns: Granted 70,718 shares @ $0
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy